# In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs

> **Newsylist Open Intelligence Dossier** · First detected: 2026-08-28 18:29 UTC · Category: Business · Sources: 3 · Current Velocity: 1.3

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Fierce Pharma | ESC: AZ, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM | 2026-08-28 15:27 | [Source Link](https://news.google.com/rss/articles/CBMivwFBVV95cUxOaHluZGNvbGx2MDlKOUZENGloMzVZVW1RX0xzdzRRTHdfYlhDSXA1ZXJwd0JCRVpUeEhOUWNWcUdCUWotUERncXRPcXcxSnB1U05zMkRtNDV6aXdVQUhsVEQ4by1FU1JDRjMzR3Qyam02d2djUE1MUEt0dEczeVFFSGVkY3VmVldZN3FIeS1jM2xYdlJyMEc0NVozcEpyaUpRclYwXzRYYnctVGlkQ1dydzlEekY3dVN6eXJTc3ZvZw?oc=5) |
| Medical Xpress | Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy | 2026-08-28 15:27 | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxQMUhNLWU1OU1uZzJ2YnA0Z2I4SjhRUTZoVUpzTy1iQmdtbWRudEdDck5kTjlkc3dBLWFoMlJLeGdOUFRLa3NPR3ZwWGZsTUdIOHFDZ0dWNjF5cHl4ZHBLZ1JxQXVfQWdmRnZKbFowbFMtbFhEZWdSRjB1RDZrVU5uTDdKMmMtQmxEX2QzdElVcU5YbFJfNGk0?oc=5) |
| HCPLive | CARDIO-TTRansform: Eplontersen Misses Primary Endpoint in ATTR-CM | 2026-08-28 15:27 | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxNa2o4U1ZBS0lTd2doT3doVF9sVzZlbHIzbnNqMjhobUNERGNsQ3ZYdWNSVExmRnpUQnlBNGRnT2pBMzRrTW1wUFJ2R1hqeGo2WnRkbWlqSTI3WjNNNUJfdjBGbVpTTnRXYjZpWFdMM1pWZ3psTTBMSzBZS1hmS3k2cmk3anBnd1IzVEY0ZDZaSXBZNGZFMUZyOQ?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-08-28/in-autopsy-of-failed-heart-disease-study-astrazeneca-raises-broader-questions*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*